- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742804
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma
Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot, Phase II study of intratumoral or intralesional injection of G100 alone (Part 1) and in conjunction with topical nitrogen mustard (HN2) or radiotherapy (Part 2) in patients with CTCL to generate anti-tumor immune responses. To confirm the safety of the injections in this population, enrollment of the first four patients will be staggered by at least 21 days each. If there are no grade 3 adverse events following the first 4 injections in the first 3 patients, then subsequent patients can be enrolled without restriction to timing.
Part 1: All patients will receive 6 intratumoral G100 injections alone over 5 weeks (first dose on Day 0, second on Day 5-7, and then weekly thereafter; up to Week 5) to assess the response to G100 alone. Response in target lesions will be measured by CAILS and abscopal effect will be measured by Modified Severity Weighted Assessment Tool (MSWAT). If applicable, peripheral blood flow cytometry will be used to assess response of circulating tumor cells.
There will be a 4-week break for restaging.
Part 2: Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator. Response in target lesions will be measured by Composite assessment of index lesion severity (CAILS) and abscopal effect will be measured by MSWAT. If applicable, peripheral blood flow cytometry will be used to assess response of circulating tumor cells.
- Dose regimen interruption in a single patient may be made by the clinical investigator if it is deemed in the best interest of patient safety.
- Tumor imaging will be performed during the screening visit (baseline) in patients with blood involvement, palpable nodes, or tumor stage disease (scans done within 4 weeks of study entry are admissible), and in patients with clinically suspicious positive scans (nodes felt to be involved, standardized uptake value (SUV) 4 or greater on positron emission tomography (PET), imaging will be repeated at the completion of 6 weeks of dosing
- Circulating Sezary cells will be followed if present at baseline. Quantitation of Sezary cells will be done by flow cytometry using appropriate markers.
- Pre- and post-treatment tumor biopsies will be obtained for histologic review and exploratory immune analyses, including cell phenotype and genomic analyses of T cells. On-treatment biopsies will be performed at Week 3 of both Parts 1 and 2 of the study. Peripheral blood will be drawn for immune assays and other biomarker tests at time points listed in the Schedule of Events and Study Procedures.
Primary Objective
- To evaluate the safety and to observe clinical responses (by MSWAT and CAILS) with intratumoral G100 alone and with G100 in combination with agents to induce apoptosis (local radiotherapy or topical nitrogen mustard) in patients with CTCL.
Secondary Objectives
- To assess abscopal tumor responses in non-treated, distal tumor sites by MSWAT and CAILS tools.
- To evaluate pre-and post-regimen tumor tissue and blood for exploratory biomarkers of immunologic and tumor response.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cutaneous T-cell lymphoma with persistent, relapsed or refractory disease following at least two prior therapies including at least one systemic therapy. Patients with aggressively progressing disease as per the investigator's assessment are not eligible.
- Skin lesions accessible for intratumoral injection and at least one additional site of disease outside the radiation field for assessment of distal (abscopal) response.
- ≥ 18 years of age.
- Life expectancy of ≥ 6 months per the investigator.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Electrocardiogram (ECG) without evidence of clinically significant ischemia or arrhythmia
- If female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use two methods of birth control or is considered highly unlikely to conceive during the dosing period and for three months after last study treatment.
- If male and sexually active with a FCBP, must agree to use effective contraception such as latex condom or is sterile (e.g. following a surgical procedure) during the dosing period and for three months after last study treatment.
Exclusion Criteria:
- Cancer therapies, including chemotherapy, radiation (non-study regimen related), within 4 weeks prior to the first scheduled G100 dose; histone deacetylase (HDAC) inhibitors and retinoids or interferon (IFN) or methotrexate or extracorporeal photopheresis (ECP) within 2 weeks
- Investigational therapy within 4 weeks prior to G100 dosing
Inadequate organ function including:
- Marrow: Peripheral blood leukocyte count (WBC) < 3000/(cubic millimeter)mm3, absolute neutrophil count ≤ 1000/mm3, platelets < 100,000/mm3, or hemoglobin < 10 grams per deciliter (gm/dL).
- Hepatic: alanine aminotransferase (ALT), and aspartate aminotransferase (AST)> 2.5 x upper limit of normal (ULN), total serum bilirubin > 1.5 x ULN (patients withGilbert's Disease may be included if their total bilirubin is ≤3.0 (milligram) mg/dL)
- Renal: Serum creatinine ≤2 mg/dL
Significant immunosuppression from:
- Concurrent, recent (≤ 4 weeks ago) or anticipated treatment with systemic corticosteroids greater than a maintenance dose for adrenal insufficiency (10 mg daily)
- Other immunosuppressive medications (e.g.,methotrexate, cyclosporine, azathioprine)
- Pregnant or nursing
- Myocardial infarction within 6 months of study initiation, active cardiac ischemia or New YorkHeart Association (NYHA) Grade III or IV heart failure
- History of other cancer within 2 years (except non-melanoma cutaneous malignancies, treated prostate cancer and cervical carcinoma in situ). Chronic lymphocytic leukemia (CLL) or low grade B-cell lymphoma will be considered on a case-by-case basis.
- Recent (< 1 week ago) clinically significant infection or active tuberculosis or evidence of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
- Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease.
- Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were transient and have completely resolved and require no ongoing therapy.
- Psychiatric, other medical illness or other condition that in the opinion of the principal investigator prevents compliance with study procedures or ability to provide valid informed consent.
- History of significant adverse or allergic reaction to any component of G100 trial regimens.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: G100 injections
All patients will receive 6 intratumoral G100 injections alone over 5 weeks.
There will be a 4-week break for restaging.
Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy.
After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
|
G100 agent is a potent Toll-like receptor (TLR)4 agonist.
G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE).
GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response will be assessed with the modified Severity Weighted Assessment Tool
Time Frame: From baseline through follow-up, up to 12 months.
|
Clinical response will be assessed with the modified Severity Weighted Assessment Tool [mSWAT].
|
From baseline through follow-up, up to 12 months.
|
Clinical response will be assessed by the composite assessment of index lesion severity
Time Frame: From baseline through follow-up, up to 12 months.
|
Clinical response will be assessed by the composite assessment of index lesion severity [CAILS])
|
From baseline through follow-up, up to 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abscopal tumor response will be assessed with the modified Severity Weighted Assessment Tool
Time Frame: From baseline through follow-up, up to 12 months.
|
Tumor response will be assessed with the modified Severity Weighted Assessment Tool [mSWAT].
|
From baseline through follow-up, up to 12 months.
|
Abscopal tumor response will be assessed by the composite assessment of index lesion severity
Time Frame: From baseline through follow-up, up to 12 months.
|
Tumor response will be assessed by the composite assessment of index lesion severity [CAILS]).
|
From baseline through follow-up, up to 12 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francine Foss, MD, Yale University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000021483
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, T-Cell, Cutaneous
-
University of WashingtonNational Cancer Institute (NCI)TerminatedCutaneous T-cell Lymphoma Stage I | Cutaneous T-cell Lymphoma Stage II | Cutaneous T-cell Lymphoma Stage III | Cutaneous T-cell Lymphoma Stage IVUnited States
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
Weiyun AiCelgene CorporationCompletedLymphoma | T-Cell Lymphoma | Cutaneous LymphomaUnited States
-
Dana-Farber Cancer InstituteRecruitingCutaneous T Cell Lymphoma | Peripheral T Cell LymphomaUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Northwestern UniversityNot yet recruitingCutaneous T Cell LymphomaUnited States
-
Universitätsmedizin MannheimKlinikum Ludwigshafen; Wuerzburg University Hospital; KKS Netzwerk; Klinikum Minden and other collaboratorsCompletedCutaneous T Cell LymphomaGermany
-
Codiak BioSciencesTerminatedCutaneous T-cell Lymphoma (CTCL)United Kingdom
Clinical Trials on Intratumoral G100
-
Immune DesignTerminatedMelanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung CancerUnited States
-
Sichuan Kelun Pharmaceutical Research Institute...Recruiting
-
Pusan National University HospitalNot yet recruitingLung CancerKorea, Republic of
-
Radboud University Medical CenterTerumo Medical Corporation; Quirem Medical B.V.Recruiting
-
Immorna Biotherapeutics, Inc.RecruitingMalignant Solid Tumor | Cutaneous TumorChina
-
Pusan National University HospitalRecruitingNon Small Cell Lung Cancer | EGFR Gene MutationKorea, Republic of
-
Pusan National University HospitalNot yet recruiting
-
Philogen S.p.A.CompletedMalignant MelanomaAustria, Germany
-
Stanford UniversityNational Institutes of Health (NIH)TerminatedLiver CancerUnited States